Rumor Mill: Novartis may bid for Bayer

Bayer stock is humming today on rumors that Novartis will mount a buyout of the giant German pharma company. European wire services quoted an offering price of €70 per share (about $94), citing anonymous traders--and giving investors plenty of room to buy Bayer stock. The company currently has a market value of $56.5 billion and the supposed Novartis offer would value it at $73.1 billion.

Adding fuel to the rumors, a Novartis spokesman offered a mere "no comment" rather than a "no" when asked about a Bayer offer. And flush with the cash it got from its sale of Gerber to Nestle, the company has said it's looking at possible acquisitions. But some pharmaceuticals analysts said a deal seemed unlikely. Bayer only just completed its acquisition of Schering, for one thing, and the quoted price seems a bit high. 

- read the report from MarketWatch

Related Articles:
NCI cancels Novartis cancer study. Report
Australia bans Novartis' Prexige. Report
Novartis shares slide after Zelnorm gets yanked. Report
Bayer plans to beef up biotech pipeline. Report 

Free Webinar

From Patient Adherence to Manufacturing Ease - Why Softgels Make Sense for Rx

THIS WEEK: Join Thermo Fisher Scientific’s upcoming webinar to learn why softgels offer numerous benefits for Rx drug development, including enhanced bioavailability, patient compliance and easy scale-up. Register Today!

Suggested Articles

North Korean hackers were accused of posing as corporate recruiters in a scheme to breach AstraZeneca's computer systems and steal COVID-19 research.

The FDA has delayed its review of Revance's frown-line injection candidate after it failed to inspect a key manufacturing facility on time.

McKinsey & Company helped guide Purdue's strategy for years and pitched the idea of rebates to distributors for overdoses, according to the NYT.